Alder BioPharmaceuticals wants to alter the way we treat some common ailments. Using a proprietary yeast-based development process it calls MabXpress, the company creates antibodies to improve existing treatments. It targets ailments that have never been treated with antibodies before. The company has no approved products but its lead candidate is ALD403, a migraine prevention medication. Next up is Clazakizumab, being developed by partner Bristol-Myers Squibb(BMS), that treats rheumatoid and psoriatic arthritis. Alder has several other non-specified products in early development as well. The company was formed in 2002 and went public in 2014.